Why is Glenmark Pharma falling/rising?

As of 12-Aug, Glenmark Pharmaceuticals Ltd. is experiencing a price increase, currently at 2,053.15, which reflects a rise of 6.65 or 0.32%. The stock has shown a positive trend over the last two days, gaining 1.72% during this period. Despite a slight decline of 5.89% over the past month, the stock has performed well year-to-date with a return of 27.62%. The company has demonstrated strong financial performance, with positive results for the last four consecutive quarters and a significant increase in profits, which has contributed to a favorable perception among investors. Additionally, the stock's low Debt to EBITDA ratio and high institutional holdings indicate a solid financial foundation and confidence from larger investors.
In the broader market context, Glenmark's short-term performance contrasts with the benchmark Sensex, which has declined by 0.59% over the past week. This indicates that Glenmark is outperforming the market in the short term, which may attract more investor interest. The stock's liquidity remains adequate, although there has been a decrease in delivery volume, suggesting a potential caution among retail investors. Overall, the combination of strong financial results, consistent returns over the years, and favorable valuation compared to peers supports the stock's upward movement despite some short-term volatility.